ASBP
Aspire Biopharma·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
ASBP fundamentals
Aspire Biopharma (ASBP) released its earnings on Aug 13, 2025: revenue was -- (YoY 0.00%), beat estimates; EPS was -0.04 (YoY +42.86%), missed estimates.
Revenue / YoY
--
0.00%
EPS / YoY
-0.04
+42.86%
Report date
Aug 13, 2025
EPS
Revenue
Revenue & Expenses
ASBP has released its 2025 Q3 earnings report, with revenue of 1.94K, reflecting a YoY change of NaN%, and net profit of -1.85M, showing a YoY change of -755.64%. The Sankey diagram below clearly presents ASBP's revenue sources and cost distribution.
Key Indicators
Aspire Biopharma (ASBP) key financial stats and ratios, covering profitability, financial health, and leverage.
Aspire Biopharma (ASBP)'s revenue and profit trends over recent years, visualized with a waterfall chart to showcase the revenue-to-profit funnel.
Trend
Breakdown
Aspire Biopharma (ASBP)'s asset and liability trends over recent years, visualized with a waterfall chart to illustrate changes in its asset-liability structure.
Trend
Breakdown
Aspire Biopharma (ASBP)'s cash flow trends over recent years, visualized with a waterfall chart to illustrate changes in its operating, investing, and financing cash flows.
Trend
Breakdown
Where does Aspire Biopharma (ASBP) generate its revenue? Explore its key revenue streams and top earning regions.
By Business
Data source:
By Region
Data source:
Track Aspire Biopharma (ASBP) Dividend Yield, Payout Ratio & Sustainability Through Its Dividend History
Payout Ratio
Dividend Yield
You can ask Aime
What is the market's earnings forecast for Aspire Biopharma next quarter?What is Aspire Biopharma's latest dividend and current dividend yield?What were the key takeaways from Aspire Biopharma's earnings call?What is the revenue and EPS growth rate for Aspire Biopharma year over year?What does Aspire Biopharma do and what are its main business segments?What is Aspire Biopharma's gross profit margin?What were the key takeaways from Aspire Biopharma’s earnings call?What guidance did Aspire Biopharma's management provide for the next earnings period?
